<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=601572900419438&amp;ev=PageView&amp;noscript=1">

News & Articles


Northway Biotechpharma is Changing its Management Structure and Appoints Giedrius Žunda as Chief Executive Officer

Biotechpharma UAB, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, is pleased to announce the appointment of Giedrius Žunda as Chief Executive Officer effective from 3 December 2018.

Mr. G. Žunda has more than 16 years of experience with Sicor Biotech UAB, leading biotech company in Central and Eastern Europe, and Teva Pharmaceutical Industries Ltd, the largest generic company in the world. He began his career with Sicor Biotech in 2002 as Process Development Manager and with Teva in 2004, steadily advancing within the organization and most recently serving as Site General Manager of Biologics Plant and member of the Board of Sicor Biotech UAB, Teva’s Lithuanian subsidiary. Prior to joining Teva, he worked for Biocentras UAB, a biotech company, developing cleaning agents and OTC products. Mr. G. Žunda earned a master’s degree from Vilnius Gediminas Technical University.

Dr. Vladas Algirdas Bumelis, the CEO and the founder of Biotechpharma, commented: “I’m pleased to announce the appointment of Giedrius, who is my student and long-term ally, as Chief Executive Officer. He is an experienced, well-respected and talented executive. Giedrius brings a strong track record of operational excellence, strategic growth, people leadership and biologics manufacturing and supply chain management. We are confident that his leadership style and industry and operational expertise are the right fit for Biotechpharma.”

Commenting on the opportunities ahead for Biotechpharma, Mr. G. Žunda said: “I am excited to be given this opportunity at Biotechpharma. I look forward to working with Biotechpharma’s experienced management team, who have been instrumental in positioning the company’s CDMO business to capitalize on current trends in the market. I see a great opportunity to leverage the company’s vertically integrated business model and to lead its talented employees to deliver increased value for shareholders. I look forward to leading this organization to its next stage of evolution.”

Dr. V.A. Bumelis will resign as the CEO as from 3 December 2018 and will take up the position of the Chairman of the Board of Directors of Biotechpharma. He will ensure smooth management transition and oversee the business, focusing more on strategic development of the company, increasing its projects portfolio and making the company a larger player on the international stage.